Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- 28 July 2016
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 375 (4), 345-356
- https://doi.org/10.1056/nejmoa1512711
Abstract
Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1.Keywords
This publication has 16 references indexed in Scilit:
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsThe Lancet, 2015
- Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasisJournal of Dermatological Treatment, 2014
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsThe New England Journal of Medicine, 2014
- Immunology of PsoriasisAnnual Review of Immunology, 2014
- Dermal γδ T cells — A new player in the pathogenesis of psoriasisInternational Immunopharmacology, 2013
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for PsoriasisThe New England Journal of Medicine, 2012
- PsoriasisThe New England Journal of Medicine, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- The cytokine and chemokine network in psoriasisClinics in Dermatology, 2007
- A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17Nature Immunology, 2005